Michael G Saunders

Address:

4365 W Pheasant Gln Dr, Salt Lake Cty, UT 84120

VIN:

1J4BA6H19AL112618

Make:

JEEP

Model:

WRANGLER UNLIMITED

Year:

2010

US Patent:

20090275583, Nov 5, 2009

Filed:

Apr 13, 2009

Appl. No.:

12/422767

Inventors:

Kraig Yager - Salt Lake City UT, US
In Chul Kim - Salt Lake City UT, US
Michael Saunders - Salt Lake City UT, US
David Gerrish - Salt Lake City UT, US
Dange Vijay Kumar - Salt Lake City UT, US
Mark B. Anderson - Salt Lake City UT, US

Assignee:

Myriad Genetics, Incorporated - Salt Lake City UT

International Classification:

A61K 31/5375
C07D 265/30
A61P 31/18

US Classification:

5142378, 544162

Abstract:

The invention relates to compounds, pharmaceutical compositions and methods useful for treating viral infection.

US Patent:

20120058997, Mar 8, 2012

Filed:

Jul 21, 2011

Appl. No.:

13/187903

Inventors:

Yong Xu - Midvale UT, US
Benjamin G. Brenning - Guadalajara, MX
Steven G. Kultgen - Salt Lake City UT, US
Xiaohui Liu - Holladay UT, US
Michael Saunders - Sandy UT, US

Assignee:

SuperGen, Inc. - Dublin CA

International Classification:

A61K 31/519
A61K 31/5025
A61P 35/00
A61K 31/5377
A61P 29/00
C07D 487/04
A61K 31/541

US Classification:

5142285, 544281, 5142593, 544236, 514248, 544 582, 544117, 5142332

Abstract:

The present invention provides protein kinase inhibitors comprising imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine compounds of the following structure (I) and (II):or a stereoisomer, prodrug or pharmaceutically acceptable salt thereof, wherein R, R, Rand X are as defined herein. Compositions and methods for using the same in the treatment of cancer and other Pim kinase-associated conditions are also disclosed.

US Patent:

20120122840, May 17, 2012

Filed:

Sep 23, 2011

Appl. No.:

13/243876

Inventors:

Dange Vijay Kumar - Salt Lake City UT, US
Ian A. McAlexander - Salt Lake City UT, US
Matthew Gregory Bursavich - Needham MA, US
Christophe Hoarau - Pleasant Hill CA, US
Paul M. Slattum - Salt Lake City UT, US
David A. Gerrish - Lakewood OH, US
Jeffrey W. Lockman - Princeton Junction NJ, US
Weston R. Judd - Farmington UT, US
Michael Saunders - Sandy UT, US
Daniel P. Parker - Salt Lake City UT, US
Daniel Feodore Zigar - Salt Lake City UT, US
In Chul Kim - Sandy UT, US
J. Adam Willardsen - Riverton UT, US
Kraig M. Yager - Salt Lake City UT, US
Mark D. Shenderovich - Salt Lake City UT, US
Brandi L. Williams - Holladay UT, US
Keith D. Tardif - Riverton UT, US

Assignee:

Myrexis, Inc. - Salt Lake City UT

International Classification:

A61K 31/541
C07D 473/32
G01N 33/567
A61K 31/5377
A61P 35/00
C07D 473/16
A61K 31/52

US Classification:

51421021, 544277, 544118, 544 582, 544 82, 5142634, 5142632, 51426324, 5142342, 51426322, 51425216, 5142285, 5142325, 435 723, 435 721

Abstract:

The invention relates to compounds, pharmaceutical compositions, and uses thereof, including therapeutic uses thereof, such as methods useful for treating cancer.

US Patent:

20210369753, Dec 2, 2021

Filed:

Apr 26, 2021

Appl. No.:

17/240834

Inventors:

- American Fork UT, US
Michael Saunders - American Fork UT, US

International Classification:

A61K 31/7048
A61K 36/61
A61K 31/26
A61K 36/185
A61K 31/216
A61K 31/353
A61K 35/644
A61K 36/23
A61K 36/9064
A61K 36/258
A61K 31/11
A61K 31/235
A61K 35/20
A61K 31/715
A61K 38/40
A61K 33/30
A61K 9/48
A61P 37/04
A61P 31/04

Abstract:

Described, among other things, are dosage forms for administration to a subject, the dosage forms having at least six ingredients are selected are from the group consisting of clove powder, rutin, hesperidin, baicalin, sulforaphane, moringa leaf extract, rosmarinic acid, guava leaf extract, , EGCG, propolis, coriander extract, cardamom extract, cinnamaldehyde, chlorogenic acid, caper fruit, vescalagin, nutmeg extract, and naringenin. The dosage forms can serve as inhibitors of quorum sensing by infectious agents. The described combinations of selected natural products have the ability to inhibit quorum sensing. Quorum sensing is a means by which bacteria and viruses communicate with each other and induce virulence in the body. This combination of natural products is preferably included in nutraceutical formulations in order to promote human immune health.

US Patent:

20210238183, Aug 5, 2021

Filed:

Nov 5, 2020

Appl. No.:

17/090857

Inventors:

- Cambridge MA, US
Benjamin Gary Brenning - Zapopan Guadalajara, MX
Steven G. Kultgen - Salt Lake City UT, US
Xiaohui Liu - Holladay UT, US
Michael David Saunders - Sandy UT, US

International Classification:

C07D 487/04
C07D 471/04

Abstract:

The present invention provides protein kinase having one of the following structures (I), (II) or (III):or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R, Rand X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.

US Patent:

20210002233, Jan 7, 2021

Filed:

Jul 15, 2020

Appl. No.:

16/930254

Inventors:

- Cambridge MA, US
Yong XU - Midvale UT, US
Michael David SAUNDERS - Sandy UT, US
Xiaohui LIU - Holladay UT, US
Scott Albert PEARCE - Clearfield UT, US
Kevin Bret WRIGHT - Cottonwood Heights UT, US
Jason Marc FOULKS - Sandy UT, US
Kenneth Mark PARNELL - Kaysville UT, US
Steven Brian KANNER - Salt Lake City UT, US
David Lee VOLLMER - South Jordan UT, US
Jihua LIU - San Marcos CA, US

International Classification:

C07D 231/14
C07D 231/38
C07F 9/6503
C07D 403/12
C07D 401/14
C07D 405/14
C07D 231/16
C07D 401/12
C07D 403/14
C07D 405/12
C07D 409/12
C07D 409/14
C07D 413/12
C07D 417/12
C07D 417/14
A61P 11/00
A61P 43/00
A61P 35/00
A61K 31/4155

Abstract:

Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I):including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R, R, R, Rand Rare as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

US Patent:

20200215084, Jul 9, 2020

Filed:

Mar 19, 2020

Appl. No.:

16/823739

Inventors:

Michael Saunders - Orem UT, US

International Classification:

A61K 31/618
A61K 31/355
A61K 47/12
A61P 25/04
A61K 31/198

Abstract:

The present invention includes a composition and method of producing aspirin in situ, the method comprising: identifying a subject in need of aspirin or aspirin-like compounds; and providing the subject with a composition comprising: a source of methyl salicylate, an acetyl donor, and L-Arginine, wherein the composition is effective to produce aspirin-triggered resolvins in the subject without the deleterious effect of the aspirin or aspirin-like compounds in the stomach.

US Patent:

20200109120, Apr 9, 2020

Filed:

Sep 26, 2019

Appl. No.:

16/584912

Inventors:

- Lehi UT, US
Yong XU - Midvale UT, US
Michael David SAUNDERS - Sandy UT, US
Xiaohui LIU - Holladay UT, US
Scott Albert PEARCE - Clearfield UT, US
Kevin Bret WRIGHT - Cottonwood Heights UT, US
Jason Marc FOULKS - Sandy UT, US
Kenneth Mark PARNELL - Kaysville UT, US
Steven Brian KANNER - Salt Lake City UT, US
David Lee VOLLMER - South Jordan UT, US
Jihua LIU - San Marcos CA, US

International Classification:

C07D 231/14
C07D 231/38
C07F 9/6503
C07D 403/12
C07D 401/14
C07D 405/14
C07D 231/16
C07D 401/12
C07D 403/14
C07D 405/12
C07D 409/12
C07D 409/14
C07D 413/12
C07D 417/12
C07D 417/14

Abstract:

Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I):including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R, R, R, Rand Rare as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.